Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Journal of Pharmacology

• Publication date

  2010-10-25

• Fields of study

  Medicine, Chemistry, Psychology

• Identifiers
  DOI 10.1016/j.ejphar.2010.07.036PMID 20674566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activation of nociceptin/orphanin FQ‐NOP receptor system inhibits tyrosine hydroxylase phosphorylation, dopamine synthesis, and dopamine D1 receptor signaling in rat nucleus accumbens and dorsal striatum

  2008cited by this paper
• xpression of morphine-conditioned place preference is more vulnerable than aloxone-conditioned place aversion to disruption by nociceptin in mice

  2008cited by this paper
• The endogenous OFQ/N/ORL-1 receptor system regulates the rewarding effects of acute cocaine.

  2008cited by this paper
• The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential

  2008cited by this paper
• Endogenous Nociceptin (Orphanin FQ) Suppresses Basal Hedonic State and Acute Reward Responses to Methamphetamine and Ethanol, but Facilitates Chronic Responses

  2008cited by this paper
• Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat.

  2008cited by this paper
• The Nociceptin/Orphanin FQ Receptor Agonist Ro 64-6198 Reduces Alcohol Self-Administration and Prevents Relapse-Like Alcohol Drinking

  2007cited by this paper
• REVIEW ON CPP: Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade

  2007cited by this paper
• Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.

  2007cited by this paper
• Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats.

  2006cited by this paper
• The effect of a systemically active ORL-1 agonist, Ro 64-6198, on the acquisition, expression, extinction, and reinstatement of morphine conditioned place preference.

  2005cited by this paper
• Nociceptin/orphanin FQ modulation of rat midbrain dopamine neurons in primary culture.

  2004cited by this paper
• Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats

  2004cited by this paper
• Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice

  2004cited by this paper
• [3H]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain.

  2003cited by this paper
• Orphanin FQ/nociceptin blocks methamphetamine place preference in rats

  2003cited by this paper
• Nociceptin inhibits acquisition of amphetamine-induced place preference and sensitization to stereotypy in rats.

  2003cited by this paper
• Acquisition, Expression, and Reinstatement of Ethanol-Induced Conditioned Place Preference in Mice: Effects of Opioid Receptor-Like 1 Receptor Agonists and Naloxone

  2003cited by this paper
• Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.

  2003cited by this paper
• Orphanin FQ/nociceptin but not Ro 65-6570 inhibits the expression of cocaine-induced conditioned place preference

  2002cited by this paper
• Lack of sensitization during place conditioning in rats is consistent with the low abuse potential of tramadol.

  2002cited by this paper
• The orphanin receptor agonist RO 64-6198 does not induce place conditioning in rats

  2002cited by this paper
• Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats

  2001cited by this paper
• In vitro inhibitory effects of J-113397 on nociceptin/orphanin FQ-stimulated.

  2001cited by this paper
• Effect of nociceptin/orphanin FQ on the rewarding properties of morphine.

  2000cited by this paper
• In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.

  2000cited by this paper
• Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system.

  2000cited by this paper
• A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat.

  2000cited by this paper
• Nociceptin differentially affects morphine-induced dopamine release from the nucleus accumbens and nucleus caudate in rats.

  2000cited by this paper
• Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties.

  2000cited by this paper
• High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor.

  2000cited by this paper
• Nociceptin/orphanin FQ and drugs of abuse.

  2000cited by this paper
• Orphanin FQ/Nociceptin Modulation of Mesolimbic Dopamine Transmission Determined by Microdialysis

  1999cited by this paper
• Orphanin FQ/nociceptin blocks acquisition of morphine place preference.

  1999cited by this paper
• Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).

  1999cited by this paper
• 8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists.

  1999cited by this paper
• Effect of nociceptin on alcohol intake in alcohol-preferring rats

  1999cited by this paper
• Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues.

  1998cited by this paper
• Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats.

  1996cited by this paper
• The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion.

  1996cited by this paper
• Neural Mechanisms of Drug Reinforcement a

  1992cited by this paper

• Opioid Antagonists as a Potential Novel Class of Psychopharmacological Agents for Management of Anhedonia

  2026cites this paper
• Pharmacological blockage of NOP receptors decreases ventral tegmental area dopamine neuronal activity through GABAB receptor-mediated mechanism.

  2024cites this paper
• Interactions of pain and opioids on conditioned place preference in rodents

  2024influential citation
• Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments

  2023cites this paper
• Oxycodone, an opioid like the others?

  2023cites this paper
• Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics

  2022cites this paper
• Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics

  2022cites this paper
• Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain

  2022cites this paper
• Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

  2021cites this paper
• Involvement of the nociceptin opioid peptide receptor in morphine-induced antinociception, tolerance and physical dependence in female mice

  2021cites this paper
• Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists

  2021cites this paper
• Bone Cancer Pain, Mechanism and Treatment

  2021cites this paper
• Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse

  2020cites this paper
• Effects of non-peptide nociceptin/orphanin FQ receptor ligands on methylphenidate-induced hyperactivity in mice: Implications for bipolar disorders.

  2020cites this paper
• Biased Opioid Ligands

  2020cites this paper
• NOP Receptor Agonist Ro 64-6198 Decreases Escalation of Cocaine Self-Administration in Rats Genetically Selected for Alcohol Preference

  2019cites this paper
• NOP agonist action of cebranopadol counteracts its liability to promote physical dependence

  2019cites this paper
• Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors.

  2019cites this paper
• NOP-Related Mechanisms in Substance Use Disorders.

  2019cites this paper
• Potent and selective NOP receptor activation reduces cocaine self‐administration in rats by lowering hedonic set point

  2019cites this paper
• The nociceptin/orphanin FQ receptor system as a target to alleviate cancer‐induced bone pain in rats: Model validation and pharmacological evaluation

  2019cites this paper
• Low-Dose Methamphetamine Addiction Induced Opioid Receptor Sensitization in Polydrug-Dependent Mice

  2018cites this paper
• The Nociceptin Receptor (NOP) Agonist AT-312 Blocks Acquisition of Morphine- and Cocaine-Induced Conditioned Place Preference in Mice

  2018influential citation
• A systematic review of the role of the nociceptin receptor system in stress, cognition, and reward: relevance to schizophrenia

  2018cites this paper
• Nociceptin/orphanin FQ receptors modulate the discriminative stimulus effects of oxycodone in C57BL/6 mice.

  2018cites this paper
• NIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted

  2018cites this paper
• Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users

  2018cites this paper
• UC Office of the President Recent Work Title The Nociceptin Receptor ( NOP ) Agonist AT-312 Blocks Acquisition of Morphine-and Cocaine-Induced Conditioned Place Preference in Mice Permalink

  2018influential citation
• Mu‐opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat

  2018cites this paper
• Limited potential of cebranopadol to produce opioid‐type physical dependence in rodents

  2018cites this paper
• Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction

  2017influential citation
• Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin/Orphanin FQ Peptide Receptor Agonist Activity

  2017cites this paper
• Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats

  2017cites this paper
• Cebranopadol: novel dual opioid/NOP receptor agonist analgesic

  2017cites this paper
• Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies

  2017cites this paper
• The Nociceptin Receptor as an Emerging Molecular Target for Cocaine Addiction.

  2016cites this paper
• Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems

  2016cites this paper
• Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice.

  2016cites this paper
• Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

  2016cites this paper
• UC Office of the President Recent Work Title The Nociceptin Receptor as an Emerging Molecular Target for Cocaine Addiction Permalink

  2015cites this paper
• Behavioral architecture of opioid reward and aversion in C57BL/6 substrains

  2015cites this paper
• Conditioned Place Preference as a Preclinical Model for Screening Pharmacotherapies for Drug Abuse

  2015cites this paper
• Investigating the potential of novel bivalent pharmacophores and tetra-branched opioids to produce analgesics with diminished tolerance and dependence profiles

  2015cites this paper
• Novel approaches for the treatment of psychostimulant and opioid abuse – focus on opioid receptor-based therapies

  2014cites this paper
• Cebranopadol: A Novel Potent Analgesic Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist

  2014cites this paper
• Functional plasticity of the N/OFQ‐NOP receptor system determines analgesic properties of NOP receptor agonists

  2014influential citation
• Where do we stand in the field of anti-abuse drug discovery?

  2014cites this paper
• Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.

  2014cites this paper
• The role of the opioid system in alcohol dependence

  2014cites this paper
• The use of bifunctional NOP/mu and NOP receptor selective compounds for the treatment of pain, drug abuse, and psychiatric disorders.

  2013cites this paper
• Pharmacology of mixed NOP/mu ligands

  2013cites this paper
• Pharmacological Investigation of NOP-Related Ligands as Analgesics without Abuse Liability

  2013cites this paper
• A single compound alternative to a buprenorphine/naltrexone combination

  2012cites this paper
• Endogenous opiates and behavior: 2010.

  2011cites this paper
• Oxycodone dose-dependently imparts conditioned reinforcing properties to discrete sensory stimuli in rats.

  2011cites this paper
• Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats.

  2010cites this paper